We are live on ! Find out more
ADIL

Adial Pharmaceuticals
ADIL

21 hedge funds and large institutions have $778K invested in Adial Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

263% more capital invested

Capital invested by funds: $214K → $778K (+$564K)

40% more funds holding

Funds holding: 15 → 21 (+6)

0.42% more ownership

Funds ownership: 0.11% → 0.53% (+0.42%)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

Holders
21
Holders Change
+6
Holders Change %
+40%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$827K
2
Jane Street
Jane Street
New York
+$35.5K
3
Citadel Advisors
Citadel Advisors
Florida
+$24.6K
4
Northern Trust
Northern Trust
Illinois
+$21.4K
5
VF
Virtu Financial
New York
+$20.7K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$3.1K
2
HF
HRT Financial
New York
-$3K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$2.71K
4
SS
SBI Securities
Japan
-$81
5
TRCT
Tower Research Capital (TRC)
New York
-$8
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$562K +$827K +102,178 New
Citadel Advisors
2
Citadel Advisors
Florida
$48.3K +$24.6K +3,033 +53%
Vanguard Group
3
Vanguard Group
Pennsylvania
$34.3K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$34.3K -$2.71K -335 -5%
Jane Street
5
Jane Street
New York
$26.8K +$35.5K +4,380 +887%
Northern Trust
6
Northern Trust
Illinois
$14.5K +$21.4K +2,639 New
VF
7
Virtu Financial
New York
$14K +$20.7K +2,553 New
XT
8
XTX Topco
Cayman Islands
$11.5K +$16.9K +2,084 New
MCM
9
Manchester Capital Management
Vermont
$10.6K – – –
BlackRock
10
BlackRock
New York
$6.11K – – –
SG
11
StoneX Group
New York
$4.28K +$6.3K +778 New
TSS
12
Two Sigma Securities
New York
$3.76K +$1.37K +169 +33%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$2.66K +$3.91K +483 New
PMG
14
Private Management Group
California
$2.2K – – –
UBS Group
15
UBS Group
Switzerland
$2.02K -$3.1K -383 -51%
TRCT
16
Tower Research Capital (TRC)
New York
$295 -$8 -1 -2%
SS
17
SBI Securities
Japan
$255 -$81 -10 -18%
Bank of America
18
Bank of America
North Carolina
$45 +$8 +1 +14%
Wells Fargo
19
Wells Fargo
California
$35 – – –
HI
20
Harbour Investments
Wisconsin
$22 +$32 +4 New
AWM
21
Abound Wealth Management
Tennessee
$6 – – –
Morgan Stanley
22
Morgan Stanley
New York
$2 – – –
HF
23
HRT Financial
New York
– -$3K -448 Closed

ADIL Hedge Fund Activity: Q4 2025 in Review

21 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q4 2025, worth a combined $778K — up 263% from $214K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ADIL positions and 1 closed out — a net gain of 6 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $827K. The largest seller was UBS Group, cutting an estimated $3.1K.

  • 21 institutional investors held Adial Pharmaceuticals (ADIL) as of Q4 2025, up from 15 in Q3 2025.
  • Funds reported $778K of Adial Pharmaceuticals stock for Q4 2025, up 263% quarter-over-quarter.
  • 7 funds opened new Adial Pharmaceuticals positions in Q4 2025 and 1 closed out, a net change of +6 holders.
  • The largest Adial Pharmaceuticals buyer in Q4 2025 was Armistice Capital, an estimated $827K added.
  • The largest Adial Pharmaceuticals seller in Q4 2025 was UBS Group, an estimated $3.1K sold.

Based on aggregated 13F filings for Q4 2025.